arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Alkermes plc.

ALKS
$44.54 ▼ -1.37 (-2.98%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
69 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Good
Bullish
auto_awesome

Analytical Summary

Alkermes plc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $7.5B
Dividend Yield —
Revenue Growth 21.8% ↘
Op. Margin 7.5% ↗
ROIC 1.2% ↗
FCF / Share $0.54 ↘
Trailing P/E 445.4x
Price / Book 4.0x
FCF Yield 1.2%
Debt / Equity 0.81
info Valuation on last close. End-of-day price, Nov 5, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$480.13M
↑ +21.8% —
Net Income Profit after all expenses
$-66.48M
— 0.0% —
Operating Margin Operating profit as % of sales
7.5%
↑ +102.8% 71th
FCF / Share Free cash flow per share
$0.54
↓ -34.6% —
Long-Term Debt Long-term obligations
$1.51B
↓ -0.9% —
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
80
Returns
77
Cash Quality
86

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 69 quarters